Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPA3 | P15088 | 3/20 | 0.75 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CPA1 | P15085 | 2/20 | 0.59 |
| ▸ | CPB1 | P15086 | 1/20 | 0.59 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.56 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.53 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.52 |
| ▸ | LTA4H | P09960 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31303730 | 1.00 | CPA3 (0.75) | CPA3FOLH1CYP1A2CPA1CPB1 | |
| SCHEMBL28430963 | 1.00 | CPA3 (0.75) | CPA3FOLH1CYP1A2CPA1CPB1 | |
| SCHEMBL28600681 | 1.00 | CPA3 (0.75) | CPA3FOLH1CYP1A2CPA1CPB1 | |
| SCHEMBL26679347 | 0.98 | CPA3 (0.77) | CPA3FOLH1CYP1A2CPA1CPB1 | |
| SCHEMBL3174797 | 0.93 | CPA3 (0.80) | CPA3FOLH1CYP1A2CPA1CPB1 | |
| SCHEMBL12494537 | 0.93 | CPA3 (0.80) | CPA3FOLH1CYP1A2CPA1CPB1 | |
| Dodecanoate SCHEMBL6299036 | 0.87 | CPA3 (0.57) | CPA3FOLH1CYP1A2 | |
| SCHEMBL29088272 | 0.86 | CPA3 (1.00) | CPA3FOLH1CYP1A2CPA1CPB1 | |
| SCHEMBL3963424 | 0.86 | CPA3 (1.00) | CPA3FOLH1CYP1A2CPA1CPB1 | |
| SCHEMBL11664393 | 0.86 | FOLH1 (0.79) | CPA3FOLH1CYP1A2CPA1CPB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4700124-A2 | OLIGONUCLEOTIDE-LIGAND CONJUGATES AND PROCESS FOR THEIR PREPARATION | Alnylam Pharmaceuticals, Inc. (US) | 2026-02-25 | — | — | EP | disclosed |
| US-20250075208-A1 | OLIGONUCLEOTIDE-LIGAND CONJUGATES AND PROCESS FOR THEIR PREPARATION | BANK OF AMERICA, N.A. | 2025-03-06 | — | — | US | disclosed |
| US-12173288-B2 | Oligonucleotide-ligand conjugates and process for their preparation | ALNYLAM PHARMACEUTICALS, INC. (US) | 2024-12-24 | — | — | US | disclosed |
| US-20220348914-A1 | OLIGONUCLEOTIDE-LIGAND CONJUGATES AND PROCESS FOR THEIR PREPARATION | BANK OF AMERICA, N.A. | 2022-11-03 | — | — | US | disclosed |
| EP-4039278-A1 | OLIGONUCLEOTIDE-LIGAND CONJUGATES AND PROCESS FOR THEIR PREPARATION | Alnylam Pharmaceuticals, Inc. (US) | 2022-08-10 | — | — | EP | disclosed |
| EP-3019200-B1 | OLIGONUCLEOTIDE-LIGAND CONJUGATES AND PROCESS FOR THEIR PREPARATION | ALNYLAM PHARMACEUTICALS INC (US) | 2022-03-23 | — | — | EP | disclosed |
| US-4410461-A | Production of benzylic esters | ASHLAND OIL, INC. (US) | 1983-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220348914-A1 | OLIGONUCLEOTIDE-LIGAND CONJUGATES AND PROCESS FOR THEIR PREPARATION | IGF2R, IRS1, INSR | CPA3 4028/4885FOLH1 412/4885CYP1A2 4624/4885 |
| US-12173288-B2 | Oligonucleotide-ligand conjugates and process for their preparation | IGF2R, IRS1, INSR | CPA3 4028/4885FOLH1 412/4885CYP1A2 4624/4885 |
| US-20250075208-A1 | OLIGONUCLEOTIDE-LIGAND CONJUGATES AND PROCESS FOR THEIR PREPARATION | IGF2R, IRS1, INSR | CPA3 4028/4885FOLH1 412/4885CYP1A2 4624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.